HYPOMAGNESAEMIA AFTER INDUCTION TPF CHEMOTHERAPY FOLLOWED BY CONCOMITANT CISPLATIN/CETUXIMAB/RADIOTHERAPY (CCRT) IN LOCALLY ADVANCED HEAD AND NECK CANCER (LAHNC)

被引：0
|
作者：
Kuhar, C. Grasic [1 ]
Strojan, P. [1 ]
Zakotnik, B. [1 ]
机构：
[1] Inst Oncol, Ljubljana, Slovenia
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：320 / 321
页数：2
相关论文
共 50 条
  • [1] Induction chemotherapy (IC) and concomitant chemoradiotherapy (CCRT) for locally advanced head and neck cancer (LAHNC).
    Ferrari, D
    Jerekzec-Fossa, B
    Chiesa, F
    Rocca, A
    Ansarin, M
    Oldani, S
    Tartaro, T
    Bruschini, R
    Orecchia, R
    Foa, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 524S - 524S
  • [2] Induction chemotherapy followed by concurrent chemoradiation (CCRT) in unresectable locally advanced head and neck cancer (LAHNC)
    Rungjarassiri, S.
    Wongsrita, S.
    Chitapanarux, I.
    Klunklin, P.
    Traisathit, P.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 94 - 95
  • [3] The End of TPF Induction for locally advanced Head and Neck Cancer? Induction Chemotherapy followed by Cetuximab and Radiotherapy is not superior to concurrent Chemoradiotherapy
    Hermann, R. M.
    Christiansen, H.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (03) : 281 - 284
  • [4] TPF induction chemotherapy (CT) followed by concomitant cisplatin/radiotherapy (cCTRT) in locally advanced nasopharyngeal cancer (LANPC)
    Bossi, P.
    Parolini, D.
    Bergamini, C.
    Locati, L. D.
    Orlandi, E.
    Franceschini, M.
    Palazzi, M.
    Olmi, P.
    Potepan, P.
    Licitra, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer
    Argiris, Athanassios
    Heron, Dwight E.
    Smith, Ryan P.
    Kim, Seungwon
    Gibson, Michael K.
    Lai, Stephen Y.
    Branstetter, Barton F.
    Posluszny, Donna M.
    Wang, Lin
    Seethala, Raja R.
    Dacic, Sanja
    Gooding, William
    Grandis, Jennifer R.
    Johnson, Jonas T.
    Ferris, Robert L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (36) : 5294 - 5300
  • [6] INDUCTION CHEMOTHERAPY FOLLOWED BY CONCOMITANT RADIOTHERAPY PLUS CETUXIMAB IN PATIENTS WITH UNRESECTABLE ADVANCED HEAD AND NECK CANCER
    Calvo, M.
    Vazquez, S.
    Lozano, A.
    Teule, A.
    Manos, M.
    Nogues, J.
    Perez, X.
    Vilajosana, E.
    Elez, E.
    Mesia, R.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 221 - 221
  • [7] Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients
    Fayette, Jerome
    Bonnin, Nathalie
    Ferlay, Celine
    Lallemant, Benjamin
    Ramade, Antoine
    Favrel, Veronique
    Zrounba, Philippe
    Chabaud, Sylvie
    Pommier, Pascal
    Poupart, Marc
    Ceruse, Philippe
    [J]. ANTI-CANCER DRUGS, 2013, 24 (06) : 623 - 629
  • [8] INDUCTION CHEMOTHERAPY (CT) WITH DOCETAXEL, CISPLATIN, AND FLUOROURACIL (TPF) FOLLOWED BY CONCOMITANT CISPLATIN PLUS RADIOTHERAPY IN LOCALLY ADVANCED NASOPHARYNGEAL CANCER (NPC)
    Kerboua, E.
    Lagha, N.
    Bouzid, K.
    Chami, S.
    Mekki, F.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 324 - 324
  • [9] Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer
    Susumu Okano
    Tomohiro Enokida
    Takuma Onoe
    Yosuke Ota
    Atsushi Motegi
    Sadamoto Zenda
    Tetsuo Akimoto
    Makoto Tahara
    [J]. International Journal of Clinical Oncology, 2019, 24 : 789 - 797
  • [10] Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer
    Okano, Susumu
    Enokida, Tomohiro
    Onoe, Takuma
    Ota, Yosuke
    Motegi, Atsushi
    Zenda, Sadamoto
    Akimoto, Tetsuo
    Tahara, Makoto
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (07) : 789 - 797
12345